If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » Sales Management » Managing Sales Force » Performance Management
Download FREE Excerpt
9 Info Graphics
26 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
This study uncovers current and planned LTC sales force activities and contracting strategies that will inform pharmaceutical and biotechnology executives trying to ascertain the optimal way to proceed in the uncharted terrain of post-Medicare Part D legislation. This legislation has had and will continue to have far-reaching implications throughout the pharmaceutical and biotech industries. Many groups within the industry are scrambling to understand how to strategically respond to the new Part D environment.
This report will specifically aid industry executives in how best to direct their Long-Term Care sales forces and contracting strategies, which have been significantly impacted by the implementation of Medicare Part D. Executives can better develop their own Part D-prompted LTC strategies, by learning what other top pharmaceutical companies are doing or planning in the near future in such critical areas as field sales force structure, resource allocation, and contracting activities and strategies.
Biotech; Pharmaceutical; Health Care; Medical Device; Manufacturing
Amgen; Upsher-Smith; Talecris; Sepracor; Novo Nordisk; Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Cardinal Health; CV Therapeutics; Eisai; Forest Laboratories; Johnson & Johnson; Pfizer; Purdue; Sanofi-aventis; Schering-Plough; Ther-Rx; UCB Pharmaceuticals